Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys

T. H. Moran, P. J. Ameglio, H. J. Peyton, Gary J. Schwartz, P. R. McHugh

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The exogenous administration of the brain/gut peptide cholecystokinin (CCK) inhibits food intake in a variety of species, including subhuman primates and humans. To determine the role of endogenously released CCK in the control of food intake in rhesus monkeys, we examined the ability of the selective type A and type B CCK antagonists devazepide and L-365260 to affect total daily food intake and various meal patterns. Various doses of the antagonists were administered intragastrically 30 min before a daily 4-h feeding period. One-gram food pellets were delivered in response to lever pulls, and intake was computer monitored. Intragastric administration of the type A CCK receptor antagonist devazepide (10-320 μg/kg) significantly increased food intake in a dose-related fashion. The threshold for increasing intake was 32 μg/kg, and a maximal effect was obtained at a dose of 100 μg/kg that increased total 4-h food intake by 47%. The effect of devazepide on food intake was mediated by significant increases in the size and duration of the initial meal, lengthening of the subsequent intermeal interval, and a decrease in the satiety ratio (intermeal interval/1st meal size). In contrast, intragastric administration of the type B CCK receptor antagonist L-365260 (3.2-320 μg/kg) did not significantly affect total food intake or any of the meal parameters. These data demonstrate that endogenously released CCK acting through type A CCK receptors plays a role in regulating food intake in rhesus monkeys.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume265
Issue number3 34-3
StatePublished - 1993
Externally publishedYes

Fingerprint

Cholecystokinin B Receptor
Macaca mulatta
Eating
Devazepide
Cholecystokinin
Meals
Cholecystokinin A Receptor
Primates
Food
Peptides

Keywords

  • devazepide
  • L-365260
  • meal patterns

ASJC Scopus subject areas

  • Physiology

Cite this

Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. / Moran, T. H.; Ameglio, P. J.; Peyton, H. J.; Schwartz, Gary J.; McHugh, P. R.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 265, No. 3 34-3, 1993.

Research output: Contribution to journalArticle

@article{b9e27d00949b489f9ea745b2b71ace46,
title = "Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys",
abstract = "The exogenous administration of the brain/gut peptide cholecystokinin (CCK) inhibits food intake in a variety of species, including subhuman primates and humans. To determine the role of endogenously released CCK in the control of food intake in rhesus monkeys, we examined the ability of the selective type A and type B CCK antagonists devazepide and L-365260 to affect total daily food intake and various meal patterns. Various doses of the antagonists were administered intragastrically 30 min before a daily 4-h feeding period. One-gram food pellets were delivered in response to lever pulls, and intake was computer monitored. Intragastric administration of the type A CCK receptor antagonist devazepide (10-320 μg/kg) significantly increased food intake in a dose-related fashion. The threshold for increasing intake was 32 μg/kg, and a maximal effect was obtained at a dose of 100 μg/kg that increased total 4-h food intake by 47{\%}. The effect of devazepide on food intake was mediated by significant increases in the size and duration of the initial meal, lengthening of the subsequent intermeal interval, and a decrease in the satiety ratio (intermeal interval/1st meal size). In contrast, intragastric administration of the type B CCK receptor antagonist L-365260 (3.2-320 μg/kg) did not significantly affect total food intake or any of the meal parameters. These data demonstrate that endogenously released CCK acting through type A CCK receptors plays a role in regulating food intake in rhesus monkeys.",
keywords = "devazepide, L-365260, meal patterns",
author = "Moran, {T. H.} and Ameglio, {P. J.} and Peyton, {H. J.} and Schwartz, {Gary J.} and McHugh, {P. R.}",
year = "1993",
language = "English (US)",
volume = "265",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "3 34-3",

}

TY - JOUR

T1 - Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys

AU - Moran, T. H.

AU - Ameglio, P. J.

AU - Peyton, H. J.

AU - Schwartz, Gary J.

AU - McHugh, P. R.

PY - 1993

Y1 - 1993

N2 - The exogenous administration of the brain/gut peptide cholecystokinin (CCK) inhibits food intake in a variety of species, including subhuman primates and humans. To determine the role of endogenously released CCK in the control of food intake in rhesus monkeys, we examined the ability of the selective type A and type B CCK antagonists devazepide and L-365260 to affect total daily food intake and various meal patterns. Various doses of the antagonists were administered intragastrically 30 min before a daily 4-h feeding period. One-gram food pellets were delivered in response to lever pulls, and intake was computer monitored. Intragastric administration of the type A CCK receptor antagonist devazepide (10-320 μg/kg) significantly increased food intake in a dose-related fashion. The threshold for increasing intake was 32 μg/kg, and a maximal effect was obtained at a dose of 100 μg/kg that increased total 4-h food intake by 47%. The effect of devazepide on food intake was mediated by significant increases in the size and duration of the initial meal, lengthening of the subsequent intermeal interval, and a decrease in the satiety ratio (intermeal interval/1st meal size). In contrast, intragastric administration of the type B CCK receptor antagonist L-365260 (3.2-320 μg/kg) did not significantly affect total food intake or any of the meal parameters. These data demonstrate that endogenously released CCK acting through type A CCK receptors plays a role in regulating food intake in rhesus monkeys.

AB - The exogenous administration of the brain/gut peptide cholecystokinin (CCK) inhibits food intake in a variety of species, including subhuman primates and humans. To determine the role of endogenously released CCK in the control of food intake in rhesus monkeys, we examined the ability of the selective type A and type B CCK antagonists devazepide and L-365260 to affect total daily food intake and various meal patterns. Various doses of the antagonists were administered intragastrically 30 min before a daily 4-h feeding period. One-gram food pellets were delivered in response to lever pulls, and intake was computer monitored. Intragastric administration of the type A CCK receptor antagonist devazepide (10-320 μg/kg) significantly increased food intake in a dose-related fashion. The threshold for increasing intake was 32 μg/kg, and a maximal effect was obtained at a dose of 100 μg/kg that increased total 4-h food intake by 47%. The effect of devazepide on food intake was mediated by significant increases in the size and duration of the initial meal, lengthening of the subsequent intermeal interval, and a decrease in the satiety ratio (intermeal interval/1st meal size). In contrast, intragastric administration of the type B CCK receptor antagonist L-365260 (3.2-320 μg/kg) did not significantly affect total food intake or any of the meal parameters. These data demonstrate that endogenously released CCK acting through type A CCK receptors plays a role in regulating food intake in rhesus monkeys.

KW - devazepide

KW - L-365260

KW - meal patterns

UR - http://www.scopus.com/inward/record.url?scp=0027435239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027435239&partnerID=8YFLogxK

M3 - Article

C2 - 8214156

AN - SCOPUS:0027435239

VL - 265

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 3 34-3

ER -